Consequences of redefining Alzheimer's disease in terms of amyloid burden without regard to cognitive decline
Stephen R. Robinson
Holly M. Brothers
Maya L. Gosztyla
摘要：Alzheimer's disease (AD) redefined: For the past century, AD has been defined as a disease of progressive cognitive decline paired with a burden of amyloid-β (Aβ) plaques and pathologic tau tangles in the hippocampus and forebrain. However, a recent Framework paper jointly sponsored by the National Institute on Aging and the Alzheimer's Association (Jack et al., 2018) proposes new clas-sification guidelines for AD, which, if adopted, will have profound consequences for the future management of AD. The new guidelines redefine AD in terms of the brain's burdens of Aβ and to a lesser extent tau, regardless of cognitive status (Figure 1). This biological approach is consistent with other diseases (e.g., type 2 diabetes) that are defined and managed in terms of biomarkers, rather than on the basis of overt symptoms. This redefinition of AD is expected to greatly facilitate progress in clinical trials and therapeutics.
机标关键词：
论文发表日期：2018-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 2098-2099 )